Quince Therapeutics (QNCX)
NASDAQ:QNCX
Want to see QNCX full AI Analyst Report?
Top Page
Quince Therapeutics
(NASDAQ:QNCX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.00
▼(-27.01% Downside)
Action:Reiterated
Date:05/22/26
The score is held down primarily by weak financial performance (no revenue, sustained losses, and sizable cash burn) and bearish technicals (below key moving averages with negative MACD). Corporate events provide a partial offset via improved financing and reduced immediate delisting pressure, but valuation support is limited due to lack of dividend yield and an uninformative P/E for a loss-making biotech.
Positive Factors
Pipeline Expansion via Orphai Acquisition
Acquiring Orphai brings a clinical‑stage inhaled rapamycin program and orphan-designated indications, materially expanding Quince's R&D portfolio. This strengthens long-term product optionality in pulmonary orphan indications, diversifying risk beyond a single proprietary corticosteroid program.
Negative Factors
Pre-revenue and Persistent Cash Burn
The company remains pre-commercial with multi‑year negative operating cash flow and deeply negative free cash flow, requiring repeated external financing to fund R&D. Sustained burn without revenue increases the risk that future financing terms will be dilutive or restrictive, pressuring long‑term capital structure.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline Expansion via Orphai Acquisition
Acquiring Orphai brings a clinical‑stage inhaled rapamycin program and orphan-designated indications, materially expanding Quince's R&D portfolio. This strengthens long-term product optionality in pulmonary orphan indications, diversifying risk beyond a single proprietary corticosteroid program.
Read all positive factors
Quince Therapeutics (QNCX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.75M
Dividend YieldN/A
Average Volume (3M)8.95M
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue GrowthN/A
EPS Growth35.04%
CountryUS
Employees36
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,300,740
10 Day Avg. Volume21,870,698
30 Day Avg. Volume8,945,457
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-4.70
Price to Sales (P/S)0.00
P/FCF Ratio-4.02
Enterprise Value/Market Cap-0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit159.91
Enterprise Value/Ebitda0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Quince Therapeutics Business Overview & Revenue Model
Company Description
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides,...
How the Company Makes Money
null...
Quince Therapeutics Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
38
Negative
Cash Flow
17
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -71.00K | -142.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -54.55M | -50.29M | -35.98M | -26.82M | -50.99M | -89.97M |
| Net Income | -33.04M | -83.98M | -56.83M | -31.39M | -51.66M | -89.94M |
Balance Sheet | ||||||
| Total Assets | 26.62M | 93.52M | 114.48M | 180.20M | 103.91M | 133.23M |
| Cash, Cash Equivalents and Short-Term Investments | 18.16M | 17.75M | 40.78M | 75.06M | 90.18M | 106.80M |
| Total Debt | 406.00K | 18.36M | 14.81M | 13.81M | 453.00K | 1.16M |
| Total Liabilities | 10.95M | 129.24M | 84.33M | 95.12M | 3.32M | 14.64M |
| Stockholders Equity | 15.67M | -35.71M | 30.15M | 85.08M | 100.59M | 118.59M |
Cash Flow | ||||||
| Free Cash Flow | -39.66M | -41.78M | -32.16M | -18.45M | -44.17M | -63.11M |
| Operating Cash Flow | -39.45M | -41.42M | -31.90M | -18.29M | -44.04M | -62.93M |
| Investing Cash Flow | 24.33M | 23.23M | 21.91M | -5.76M | 18.00M | 58.95M |
| Financing Cash Flow | 27.27M | 17.91M | -4.78M | 143.00K | 707.00K | 6.81M |
Quince Therapeutics Technical Analysis
Negative
1.37
Price Trends
1.19
Negative
6.05
Negative
14.11
Negative
Market Momentum
-0.08
Negative
44.36
Neutral
65.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNCX, the sentiment is Negative. The current price of 1.37 is above the 20-day moving average (MA) of 1.18, above the 50-day MA of 1.19, and below the 200-day MA of 14.11, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 44.36 is Neutral, neither overbought nor oversold. The STOCH value of 65.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNCX.
Quince Therapeutics Risk Analysis
Quince Therapeutics disclosed 42 risk factors in its most recent earnings report. Quince Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quince Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $232.52M | -2.42 | -30.90% | ― | ― | 10.70% | |
53 Neutral | $188.12M | -8.52 | -48.20% | ― | 7336.90% | 49.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $78.02M | -0.69 | -59.06% | ― | ― | 49.00% | |
43 Neutral | $18.75M | -0.17 | 7743.57% | ― | ― | 35.04% | |
42 Neutral | $19.17M | -2.42 | -74.58% | ― | ― | 33.15% |
* Healthcare Sector Average
QNCX
Quince Therapeutics
1.15
-9.45
-89.15%
PLRX
Pliant Therapeutics
1.26
-0.18
-12.50%
NKTX
Nkarta
3.25
1.52
87.86%
ADAG
Adagene
3.97
1.89
90.41%
ANEB
Anebulo Pharmaceuticals
0.47
-0.59
-55.58%
Quince Therapeutics Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk
Positive
May 21, 2026
On March 17, 2026, Quince Therapeutics, Inc. was notified by the Nasdaq Listing Qualifications Department that it had failed to maintain the required minimum market value of listed securities of $50 million over 30 consecutive business days, putti...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Quince Therapeutics Closes Orphai Deal and Secures Funding
Positive
May 18, 2026
On May 18, 2026, Quince Therapeutics completed the stock-for-stock acquisition of clinical-stage Orphai Therapeutics, adding the LAM-001 inhaled rapamycin program and related orphan drug-designated indications to its portfolio, while also appointi...
Delistings and Listing ChangesRegulatory Filings and Compliance
Quince Therapeutics Regains Nasdaq Bid Compliance Amid Valuation Risk
Negative
Apr 28, 2026
On April 27, 2026, Quince Therapeutics said it had regained compliance with Nasdaq’s minimum bid price requirement after its shares closed at or above $1.00 for 10 consecutive business days from April 13 through April 24, 2026, leading Nasda...
Executive/Board Changes
Quince Therapeutics Appoints June Bray to Board
Positive
Apr 22, 2026
On April 22, 2026, Quince Therapeutics increased the size of its board of directors to four members and appointed June Bray as an independent Class I director, effective immediately, to serve until the 2026 annual meeting of stockholders. Bray, wh...
Business Operations and StrategyStock Split
Quince Therapeutics Announces 1-for-10 Reverse Stock Split
Neutral
Apr 9, 2026
Quince Therapeutics, Inc. will implement a 1-for-10 reverse stock split of its common stock, approved by stockholders on June 4, 2025 and authorized by the board, with the related certificate of amendment filed in Delaware on April 9, 2026 and bec...
Business Operations and Strategy
Quince Therapeutics Eliminates EIB Debt, Boosts Flexibility
Positive
Mar 30, 2026
On March 27, 2026, Quince Therapeutics paid approximately $5.5 million to the European Investment Bank to fully settle about $16.4 million in outstanding debt tied to a 2020 finance contract and related guarantees. The company announced on March 3...
Delistings and Listing ChangesRegulatory Filings and Compliance
Quince Therapeutics Faces Nasdaq Listing Compliance Deficiencies
Negative
Mar 20, 2026
On March 16, 2026, Quince Therapeutics received notice from Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, triggering a 180-day grace period to regain compliance by maintaining a closing...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.